Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Nonsense mutations create premature termination codons (PTCs), contributing to 10-30% of tumor suppressor gene mutations.
• Nonsense translational suppression using drugs like gentamicin is a potential therapy for genetic diseases and cancers.
• Developing novel agents for PTC suppression is crucial for targeted cancer therapies.

Purpose of the Study:

• To evaluate NB124, a synthetic aminoglycoside, for its efficacy in suppressing PTCs in human tumor cells.
• To investigate NB124's mechanism of action, including its effect on mRNA stability and protein production.
• To compare NB124's performance with existing readthrough inducers like gentamicin.

Main Methods:

• Utilized a reporter system to assess NB124's ability to suppress PTCs in genes like p53 and APC.
• Investigated NB124's impact on nonsense-mediated decay (NMD) of p53 mRNA.
• Quantified NB124-induced apoptosis in human tumor cells.

Main Results:

• NB124 strongly induced apoptosis in human tumor cells by promoting significant PTC readthrough.
• NB124 demonstrated suppression of PTCs in key tumor suppressor genes, including p53 and APC.
• NB124 counteracted p53 mRNA degradation via NMD, leading to full-length p53 protein production.
• The full-length p53 protein activated p53-dependent genes, resulting in high levels of apoptosis.

Conclusions:

• NB124, a next-generation aminoglycoside, effectively induces PTC readthrough and apoptosis in cancer cells.
• NB124 outperforms gentamicin in PTC suppression and exhibits dual action of readthrough induction and mRNA stabilization.
• NB124 holds significant potential for developing personalized treatments for PTC-dependent diseases and novel drugs modulating translation fidelity.